A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.
Feder A, Costi S, Rutter SB, Collins AB, Govindarajulu U, Jha MK, Horn SR, Kautz M, Corniquel M, Collins KA, Bevilacqua L, Glasgow AM, Brallier J, Pietrzak RH, Murrough JW, Charney DS. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. Am J Psychiatry. 2021 Feb 1;178(2):193-202. doi: 10.1176/appi.ajp. 2020.20050596. Epub […]
Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression.
Siegel JS, Palanca BJA, Ances BM, Kharasch ED, Schweiger JA, Yingling MD, Snyder AZ, Nicol GE, Lenze EJ, Farber NB. Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression. Psychopharmacology (Berl). 2021 Apr;238(4):1157-1169. doi: 10.1007/s00213-021-05762-6. Epub 2021 Jan 22. PMID: 33483802; PMCID: PMC7969576. Highlights: In this open-label, proof-of-principle study, adults […]
Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials.
Highlights: The rapid and robust antidepressant effects of single-dose ketamine in patients with TRD suggest that ketamine is a promising candidate for an effective therapy in patients who do not respond to conventional treatment. Our findings showed that a single administration of ketamine reduces depressive symptoms and that the initial antidepressant effects of the drug […]
Ketamine for acute suicidal ideation. An emergency department intervention: A randomized, double-blind, placebo-controlled, proof-of-concept trial.
Domany Y, Shelton RC, McCullumsmith CB. Ketamine for acute suicidal ideation. An emergency department intervention: A randomized, double-blind, placebo-controlled, proof-of-concept trial. Depress Anxiety. 2020 Mar;37(3):224-233. doi: 10.1002/da.22975. Epub 2019 Nov 16. PMID: 31733088. Highlights: A single dose of IV ketamine produced effective and rapid reductions in suicidal ideation in as little as 90 minutes. 88% […]
Efficacy of ketamine therapy in the treatment of depression.
Mandal S, Sinha VK, Goyal N. Efficacy of ketamine therapy in the treatment of depression. Indian J Psychiatry. 2019 Sep-Oct;61(5):480-485. doi: 10.4103/psychiatry.IndianJPsychiatry _484_18. PMID: 31579184; PMCID: PMC6767816. Highlight: The effect of subanesthetic dose of ketamine was assessed on depressive and anxiety symptoms. Illness severity and improvement were assessed after treatment with ketamine. Twenty-five drug-free/naïve […]
Efficacy of ketamine therapy in the treatment of depression. Indian J Psychiatry.
Mandal S, Sinha VK, Goyal N. Efficacy of ketamine therapy in the treatment of depression. Indian J Psychiatry. 2019 Sep-Oct;61(5):480-485. doi: 10.4103/psychiatry.IndianJPsychiatry _484_18. PMID: 31579184; PMCID: PMC6767816. Highlights: Administration of slow IV ketamine in patients with severe depression results in significant improvement in depression and anxiety symptoms immediately 1 hour after a single dose […]
Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study
Glue, P., Neehoff, S., Sabadel, A., Broughton, L., Le Nedelec, M., Shadli, S., McNaughton, N., & Medlicott, N. J. (2019). Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study. Journal of Psychopharmacology, 34(3), 267–272. Highlights: The purpose of this study was to replicate our earlier report […]
Ketamine for Treatment-Resistant Mood Disorders
Highlights: Strong evidence supports the rapid, although temporary, antidepressant effects of a single intravenous ketamine infusion for treatment-resistant major depressive disorder (MDD) and bipolar depression. Intravenous ketamine administration for treatment-resistant depression (TRD) is generally safe and well tolerated when administered by trained professionals. Ketamine research is transforming our understanding of the pathophysiology of mood disorders […]
Ketamine for Treatment-Resistant Mood Disorders.
Park LT, Falodun TB, Zarate CA Jr. Ketamine for Treatment-Resistant Mood Disorders. Focus (Am Psychiatr Publ). 2019 Jan;17(1):8-12. doi: 10.1176/appi.focus.20180030. Epub 2019 Jan 7. PMID: 31975953; PMCID: PMC6493154. Highlights: Strong evidence supports the rapid, although temporary, antidepressant effects of a single intravenous ketamine infusion for treatment-resistant major depressive disorder (MDD) and bipolar depression. Intravenous […]
Increased reactivity of the mesolimbic reward system after ketamine injection in patients with treatment-resistant major depressive disorder.
Sterpenich, V., Vidal, S., Hofmeister, J., Michalopoulos, G., Bancila, V., Warrot, D., Dayer, A., Desseilles, M., Aubry, J.-M., Kosel, M., Schwartz, S., & Vutskits, L. (2019). Increased reactivity of the mesolimbic reward system after ketamine injection in patients with treatment-resistant major depressive disorder. Anesthesiology, 130(6), 923–935. Highlights: As expected, ketamine administration led to an […]